The EC has granted marketing authorisation for AbbVie’s Tepkinly in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.

Servier’s head of business development Frederic Scaerou discusses the French company’s recent string of dealmaking.

Fresh with a rebrand, Cyllene will advance gene therapies built on a platform that uses a modified form of the herpes virus for delivery.

Vertex is to acquire Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.

Through predictive modelling, AI supports target identification, prediction of physicochemical properties and formulation strategy selection.

The UK Government has prioritised life science sector growth, but industry members have called for more funding.